Damora Therapeutics (DMRA) awards 1.5M options and 500K RSUs

Rhea-AI Filing Summary

Damora Therapeutics director and officer Jennifer Jarrett received new equity awards as compensation. On March 30, 2026, she was granted stock options to purchase 1,500,000 shares of common stock at an exercise price of $25.50 per share, expiring March 30, 2036. The options vest 25% on March 30, 2027 and then in equal monthly installments through March 30, 2030, subject to continued service. She also received 500,000 restricted stock units, each representing one share of common stock, vesting 25% on each anniversary of the grant date over four years, also conditioned on continued service. Following these awards, she directly holds 500,000 shares of common stock and 1,500,000 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Jarrett Jennifer

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	1,500,000	$0.00	--
Grant/Award	Common Stock	500,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 1,500,000 shares (Direct); Common Stock — 500,000 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one share of common stock of the Issuer. The RSUs will vest with respect to 25% on each anniversary of the grant date through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each such vesting date. This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on March 30, 2027 and in equal monthly installments thereafter through March 30, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Stock options granted: 1,500,000 options at $25.50 RSUs granted: 500,000 RSUs Common stock held after grants: 500,000 shares +1 more

4 metrics

Stock options granted 1,500,000 options at $25.50 Granted March 30, 2026; expire March 30, 2036

RSUs granted 500,000 RSUs Granted March 30, 2026; vest over four years

Common stock held after grants 500,000 shares Direct holdings following March 30, 2026 awards

Options held after grants 1,500,000 options Direct option holdings following March 30, 2026 award

Key Terms

restricted stock units ("RSUs"), Stock Option (right to buy), vesting, exercise price

4 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") granted to the Reporting Person."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

vesting financial

"The RSUs will vest with respect to 25% on each anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: "25.5000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jarrett Jennifer

(Last) (First) (Middle)

C/O DAMORA THERAPEUTICS, INC.,

221 CRESCENT ST, BUILDING 23, SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/30/2026		A		500,000	A	$0	500,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$25.5	03/30/2026		A		1,500,000		(2)	03/30/2036	Common Stock	1,500,000	$0.00	1,500,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one share of common stock of the Issuer. The RSUs will vest with respect to 25% on each anniversary of the grant date through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

2. This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on March 30, 2027 and in equal monthly installments thereafter through March 30, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

President and Chief Executive Officer

	/s/ Garrett Winslow, attorney-in-fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Damora Therapeutics (DMRA) report for Jennifer Jarrett?

Damora Therapeutics reported that director and officer Jennifer Jarrett received equity compensation grants. She was awarded 1,500,000 stock options and 500,000 restricted stock units on March 30, 2026, increasing her direct holdings in options and common stock of the company.

How many Damora Therapeutics (DMRA) stock options were granted to Jennifer Jarrett and at what price?

Jennifer Jarrett received 1,500,000 stock options to purchase Damora Therapeutics common stock at an exercise price of $25.50 per share. These options expire on March 30, 2036 and vest gradually from March 30, 2027 through March 30, 2030, subject to continued service.

What are the vesting terms of the restricted stock units granted to Jennifer Jarrett at Damora Therapeutics (DMRA)?

The 500,000 restricted stock units granted to Jennifer Jarrett vest over four years. Twenty-five percent vest on each anniversary of the March 30, 2026 grant date, provided she continues serving Damora Therapeutics on each vesting date, with each vested unit settling in one share of common stock.

Are Jennifer Jarrett’s Damora Therapeutics (DMRA) Form 4 transactions open-market purchases or compensation awards?

The reported Form 4 transactions are compensation-related awards, not open-market trades. Both the 1,500,000 stock options and 500,000 restricted stock units were granted at a price of $0.00 per unit as part of her equity compensation from Damora Therapeutics.

What is Jennifer Jarrett’s direct equity position in Damora Therapeutics (DMRA) after these grants?

After the reported grants, Jennifer Jarrett directly holds 500,000 shares of Damora Therapeutics common stock and 1,500,000 stock options. The stock options are exercisable at $25.50 per share and follow a multi-year vesting schedule extending through March 30, 2030.

Over what period do Jennifer Jarrett’s Damora Therapeutics (DMRA) stock options vest?

Jennifer Jarrett’s stock options vest 25% on March 30, 2027, then in equal monthly installments through March 30, 2030. Continued service to Damora Therapeutics on each vesting date is required for those installments to vest under the award’s terms.